Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation Phase 2 Study of Selinexor in Patients with MDS Refractory to Hypomethylating Agents: Interim Report PDF (1.45 MB) Read MorePaper Multiple myeloma cells sent “PAKing”! External Link Read MorePresentation Selinexor or KPT-8602 Mediated XPO1 Inhibition Synergizes with Dexamethasone to Repress Convergent Pathways in the mTORC1 Signaling Network and Drive Cell Death in Multiple Myeloma PDF (1.06 MB) Read MorePresentation KPT-9274 Inhibits Cellular NAD and Synergizes with Doxorubicin to Treat Dogs with Lymphoma PDF (972.54 KB) Read MorePresentation A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB and Non-GCB subtypes PDF (3.85 MB) Read MorePresentation Disruption of Nuclear Export with Selinexor or KPT-8602 Reduces Androgen Receptor Expression and Leads to Potent Anti-Tumor Activity in Preclinical Models of Androgen-Independent Prostate Cancer PDF (3.21 MB) Read MorePresentation p21 activated kinase 4 (pak4) as a novel therapeutic target for non-hodgkin’s lymphoma PDF (1.81 MB) Read MorePresentation Anti-tumor Activity of Palbociclib is Enhanced by Selinexor in Preclinical Models of HER2+ Breast Cancer PDF (1.33 MB) Read MorePresentation The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma PDF (1.26 MB) Read MorePresentation Novel role of XPO1 in regulating MicroRNAs related to pancreatic ductal adenocarcinoma invasion and metastasis PDF (2.61 MB) Read More Previous 1 … 3 4 5 6 7 … 22 Next